In order to enhance the ability of research and development in the
pharmaceutical industry, our company is proud to announce the construction of a new production base. The production base covering a total area of 150 mu, with a construction investment of 800,000 yuan. And has built 5500 square meters of R&D center, has been put into operation.
The establishment of the R&D center marks a significant improvement in our company's scientific research strength in the field of medicine. Currently, we have a high-level research and development team composed of 150 professional and technical personnel. They are dedicated to the research and production of series nucleoside monomers, ADC payloads, linker key intermediates, Building Block custom synthesis, small molecule CDMO services, and more.
Our ultimate goal is to help speed up the launch of new drugs and improve quality of life for patients worldwide. By leveraging continuous technological innovation and green pharmaceutical practices, we are able to provide one-stop CMC services to both domestic and foreign pharmaceutical companies, assisting with every stage of the drug lifecycle from development to application.
We understand that cost-effectiveness is critical for our customers, which is why we use sustainable and efficient production methods like continuous reactions and enzymatic catalysis to reduce costs and drive sustainable growth in orders. Our commitment to quality, innovation, and sustainability sets us apart as a leader in the pharmaceutical industry and a key partner in the global quest for improved healthcare outcomes.
Post time: Jan-28-2023